Management of Non-ST Elevation MI with Upper GI Bleed

Initial Management and Risk Stratification

For patients with NSTEMI complicated by upper GI bleeding, an individualized approach balancing the risks of thrombosis versus bleeding is recommended, with early invasive strategy for high-risk patients after hemodynamic stabilization and control of bleeding, as suggested by the American College of Cardiology and American Heart Association 1, 2
Assess cardiac risk using validated tools such as GRACE score to determine optimal timing of intervention, according to the American College of Cardiology 1, 2
Higher risk NSTEMI features include: hemodynamic instability, refractory ischemia, electrical instability, elevated cardiac biomarkers, and dynamic ECG changes, as identified by the American College of Cardiology 2, 3

Continue aspirin at low dose (81 mg daily) if possible, as it has the most favorable risk-benefit profile, according to the American Heart Association 4, 5
Consider temporarily discontinuing P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) during active bleeding, with the shortest possible interruption based on endoscopic findings and cardiac risk, as recommended by the American College of Cardiology 6, 5
Discontinue parenteral anticoagulants (UFH, LMWH, fondaparinux) during active bleeding, as suggested by the American College of Cardiology 2, 7

For high-risk NSTEMI patients with controlled GI bleeding, an early invasive strategy (within 24 hours) is recommended, according to the American College of Cardiology and American Heart Association 1, 2, 3
For initially stabilized patients with controlled bleeding, an early invasive approach (within 24 hours) is reasonable if they have high-risk features, as recommended by the American College of Cardiology 2, 3

Restart antiplatelet therapy as soon as the risk of cardiac events outweighs the risk of recurrent bleeding, according to the American College of Cardiology 6, 5
Consider using proton pump inhibitors in patients requiring triple antithrombotic therapy (anticoagulant plus dual antiplatelet therapy), as suggested by the American Heart Association 6, 5
For patients requiring long-term anticoagulation plus antiplatelet therapy, minimize the duration of triple therapy to reduce bleeding risk, as recommended by the American College of Cardiology 6

For high-risk NSTEMI patients with controlled GI bleeding, an early invasive strategy (within 24 hours) is recommended, as stated by the American Heart Association, with a focus on minimizing delay in coronary intervention to improve outcomes 8
The timing of coronary angiography should be determined by the severity of both the NSTEMI and the GI bleeding, with consideration of the patient's overall risk profile, according to the American College of Cardiology 8
Avoid prolonged delay in coronary intervention, as studies show that a strategy of "cooling-off" for 3-5 days before angiography does not improve outcomes, highlighting the importance of timely intervention in high-risk patients 8

When restarting P2Y12 inhibitors, a loading dose of clopidogrel (300-600mg) followed by 75mg daily maintenance dose is recommended when resuming therapy, as suggested by the American Heart Association 9
Aspirin should be administered at 75-162mg daily in patients with NSTEMI, according to the American College of Cardiology, to balance the risk of cardiac events and bleeding 8, 10